LifeScience Clinical & Diagnostic
Sovargen Doses First Patient in Phase Ib/IIa Trial of Kazia’s Paxalisib for Rare Epilepsies
- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...
September 23, 2026 | News
Bio-Techne Opens Düsseldorf Flagship Centre to Accelerate Life Sciences Innovation Across Europe
New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and ...
September 23, 2026 | News
XtalPi-Backed Viva-Thera Advances AI-Designed HIV Candidate to Preclinical Stage in Seven Months
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Th...
September 23, 2026 | News
Mayo Clinic Laboratories Invests in Pathology Asia to Expand Precision Diagnostics Across APAC
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH) have announced a strategic investment and collaboration aimed at expanding access to a...
September 23, 2026 | News
Singapore Approves Wegovy as First Treatment for MASH with Liver Fibrosis
ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with ...
September 23, 2026 | News
NewAmsterdam, Menarini Secure EU Approval for Obicetrapib-Based Ubeslo and Evlarco
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-s...
September 23, 2026 | News
Bestzyme Completes World’s First Automated Smart Production Line for Sweet Proteins
Bestzyme, a synthetic biology company under GenScript Biotech, announced the completion of the world's first dedicated, automated smart production li...
September 23, 2026 | News
Novartis Inks Up to $900M Global Licensing Deal with BoomRay for Radioligand Therapy Asset
Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision onco...
September 23, 2026 | News
IMPACT Therapeutics, Pharmanovia’s Senaparib Secures EU Panel Backing for Ovarian Cancer
MPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based...
September 21, 2026 | News
Massive Bio Targets South Korea Expansion for AI-Powered Oncology Trial Matching
US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and buil...
September 21, 2026 | News
Why 10,000 Koreans a Year Still Fly Abroad for Stem Cell Treatment
METHOD IN BRIEF This feature expands entry 21 of our year-end count, 2026 in 26 Numbers. Every figure is cited to a regulator publication, offi...
September 21, 2026 | Analysis
Ferronova’s Nanoparticle Platform Shows Promise for More Precise Gastric and Oesophageal Cancer Surgery
Australian medical technology company Ferronova has announced preliminary findings from the MAGMAP multi-centre trial involving 62 gastric and oesopha...
September 17, 2026 | News
Takeda’s Zasocitinib Receives US FDA Priority Review for Plaque Psoriasis
-Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for za...
September 16, 2026 | News
IonOpticks Launches Aurora Series 5 to Boost Robustness in High-Throughput Proteomics
New CoreJet™ integrated emitter technology and a redesigned nanoZero® union combine proven Aurora Series® performance with a step-change in r...
September 15, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
